Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

ions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable ureteral stent used in association with the adjunctive treatment of kidney stones.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Swedesboro, NJ (PRWEB) May 24, 2013 Dr. ... Elmer, NJ and Swedesboro, NJ, are proud to announce an ... event will take place on Saturday, June 8th from 10 ... Dr. Warmuth, Anamaria Newport, MHS, PA-C and staff will be ... dermal fillers, laser and aesthetic treatments, and provide complimentary cosmetic ...
(Date:5/24/2013)... May 24, 2013 In a ... industry suppliers will present technologies with applications in ... annual SPIE Optics and Photonics symposium ... SPIE, the international society for optics and ... multidisciplinary optical sciences and technology meeting in North ...
(Date:5/24/2013)... May 24, 2013 Bed bug cases tend ... themselves from the looming higher risk of becoming the pests' ... new bed bug guideline. In the guide, the company enumerated ... and avoiding them while traveling. , According to My ... increase of bed bug infestation during summer: the warm weather ...
(Date:5/24/2013)... Israel , May 24, 2013 ... leader in embolic protection stents, announced that Alan ... and Craig Shore , the Company,s Chief ... Investor Conference on Thursday May 30, 2013 at The Pfister ... The format of the conference includes a ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4
... N.J., Feb. 5 Genta,Incorporated (Nasdaq: GNTA ) ... Dr. Raymond P. Warrell, Jr., will provide a,company overview ... &,Investor Conference. The presentation is scheduled for Wednesday, February,13th ... New York, NY., About Genta, Genta Incorporated ...
... LOUISVILLE, Colo., Feb. 5 Replidyne, Inc.,(Nasdaq: RDYN ) ... February 26, 2008 at 4:45 P.M. ET to report 2007 ... upcoming,investor conference in February 2008., Earnings conference call ... President and CEO, and other members of Replidyne,s ...
... Mass., Feb. 5 Echo Therapeutics,Inc. (OTC Bulletin ... announced today that Patrick T. Mooney, M.D, Chairman,and ... Small-Cap Investor,Conference on February 7, 2008 at 3:50 ... The conference will be held at the Four ...
Cached Biology Technology:Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 2Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 3Echo Therapeutics to Present at RedChip Small-Cap Investor Conference 2
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
(Date:5/23/2013)... cerebral palsy with autologous cord blood. Following a cardiac ... boy had been in a persistent vegetative state ... treatment with the cord blood containing stem cells, the ... learned to speak simple sentences and to move. "Our ... the long-held doubts about the effectiveness of the new ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... November 18, 2008 -- Researchers at the University of California, ... been used to block and reverse type 1 diabetes in ... the National Academy of Sciences , was led by Jeffrey ... an expert in the field of autoimmunity. "The findings ...
... at Birmingham (UAB) Center for Education and Research on ... to study the risks and benefits of a newer ... therapies that target the immune system of patients who ... disorders. The award will allow the UAB CERTs ...
... WEST LAFAYETTE, Ind. - Materials engineers have created a ... and, if perfected, might be used for environmental cleanup, ... would last longer than conventional filters for separating oil ... oil, traits that are usually mutually exclusive. Researchers attached ...
Cached Biology News:Musculoskeletal center wins $2.2 million for drug safety 2New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
... StabilGuard Biomolecule Stabilizer is a bovine protein-free ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2, and does ... maintains the activity of antibodies and other ...
Biology Products: